Skip to main content
. 2021 Nov 24;9(12):1383. doi: 10.3390/vaccines9121383
COVID-19 Coronavirus Disease 2019
SARS-CoV-2 Severe acute respiratory syndrome coronavirus-2
VOCs Variants of concern
RBD Receptor-binding domain
hACE2 Human angiotensin-converting enzyme 2
HRP Horseradish peroxidase
MPL Monophosphoryl lipid A
DMEM Dulbecco’s Modified Eagle Medium
NT50 Neutralizing antibody titer needed to neutralize 50% of viral infectivity.